Timeline
Genflow Biosciences
Genflow reports sustained efficacy in dog longevity trial
Genflow Chairman to Join RNA Therapeutics Panel at BIO International Convention
Genflow to present gene therapy data at Toronto longevity summit
Genflow Biosciences highlights progress with focus on R&D
Genflow Biosciences shares higher as 'tier-1' talks advance
Genflow Biosciences secures fully funded LNP collaboration with Acuitas Therapeutics
Genflow’s SIRT6 patent fence widens
Genflow says its gene therapy for dogs maintains safety and efficacy three months after dosing
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.